Evidence map›Paper›PMID 36745545›Full record

ArticleMicrobial genomics2023

The use of representative community samples to assess SARS-CoV-2 lineage competition: Alpha outcompetes Beta and wild-type in England from January to March 2021.

Oliver Eales, Andrew J Page, Sonja N Tang, Caroline E Walters, Haowei Wang, David Haw, Alexander J Trotter, Thanh Le Viet, Ebenezer Foster-Nyarko, Sophie Prosolek and 12 more

Open access · goldAbstract read
In one paragraph

Article in Microbial genomics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Development of synthetic antigen vaccines for COVID-19.Human vaccines & immunotherapeutics · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 4 institutions in 1 country.

Oliver EalesSchool of Public Health, Imperial College London, London, UK.
Andrew J PageQuadram Institute, Norwich, UK.
Sonja N TangSchool of Public Health, Imperial College London, London, UK.
Caroline E WaltersSchool of Public Health, Imperial College London, London, UK.
Haowei WangSchool of Public Health, Imperial College London, London, UK.
David HawSchool of Public Health, Imperial College London, London, UK.
Alexander J TrotterQuadram Institute, Norwich, UK.
Thanh Le VietQuadram Institute, Norwich, UK.
Ebenezer Foster-NyarkoQuadram Institute, Norwich, UK.
Sophie ProsolekQuadram Institute, Norwich, UK.
Christina AtchisonSchool of Public Health, Imperial College London, London, UK.
Deborah AshbySchool of Public Health, Imperial College London, London, UK.
Graham CookeDepartment of Infectious Disease, Imperial College London, London, UK.
Wendy BarclayDepartment of Infectious Disease, Imperial College London, London, UK.
Christl A DonnellySchool of Public Health, Imperial College London, London, UK.
Justin O'GradyQuadram Institute, Norwich, UK.
Erik VolzSchool of Public Health, Imperial College London, London, UK.
The Covid-Genomics Uk Cog-Uk ConsortiumCOVID-19 Genomics UK Consortium, UK.
Ara DarziImperial College Healthcare NHS Trust, London, UK.
Helen WardSchool of Public Health, Imperial College London, London, UK.
Paul ElliottSchool of Public Health, Imperial College London, London, UK.
Steven RileySchool of Public Health, Imperial College London, London, UK.
Imperial College London · GBQuadram Institute · GBImperial College Healthcare NHS Trust · GBUniversity of Oxford · GB

Funding

Medical Research Council MC_PC_17114Medical Research Council MC_PC_19012Medical Research Council MR/J008761/1Medical Research Council MR/L01341X/1Medical Research Council MR/R015600/1Wellcome Trust 200861/Z/16/Z
6 · The paper itself

Abstract

Genomic surveillance for SARS-CoV-2 lineages informs our understanding of possible future changes in transmissibility and vaccine efficacy and will be a high priority for public health for the foreseeable future. However, small changes in the frequency of one lineage over another are often difficult to interpret because surveillance samples are obtained using a variety of methods all of which are known to contain biases. As a case study, using an approach which is largely free of biases, we here describe lineage dynamics and phylogenetic relationships of the Alpha and Beta variant in England during the first 3 months of 2021 using sequences obtained from a random community sample who provided a throat and nose swab for rt-PCR as part of the REal-time Assessment of Community Transmission-1 (REACT-1) study. Overall, diversity decreased during the first quarter of 2021, with the Alpha variant (first identified in Kent) becoming predominant, driven by a reproduction number 0.3 higher than for the prior wild-type. During January, positive samples were more likely to be Alpha in those aged 18 to 54 years old. Although individuals infected with the Alpha variant were no more likely to report one or more classic COVID-19 symptoms compared to those infected with wild-type, they were more likely to be antibody-positive 6 weeks after infection. Further, viral load was higher in those infected with the Alpha variant as measured by cycle threshold (Ct) values. The presence of infections with non-imported Beta variant (first identified in South Africa) during January, but not during February or March, suggests initial establishment in the community followed by fade-out. However, this occurred during a period of stringent social distancing. These results highlight how sequence data from representative community surveys such as REACT-1 can augment routine genomic surveillance during periods of lineage diversity.

Indexed as

COVID-19SARS-CoV-2AdolescentAdultEnglandHumansMiddle AgedPhylogenyYoung Adult

Identifiers

PMID36745545
PMCPMC9997751
OpenAlexW4319294603

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.